Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC/AHA guidelines
Source : https://www.sciencedirect.com/science/article/pii/S1319016423000841?via=ihub
Statins are drugs of choice in treating hyperlipidemia and preventing or reducing cardiovascular diseases. Explore statins utilization and expenditure trends in the United States before and after the publication of...
Conclusion: The proportion of individuals who used statins significantly increased following the adoption of the 2013 ACC/AHA guidelines. The findings, however, demonstrated suboptimal prescribing trends of high-intensity statins, which need to be addressed by the stakeholders to maximize medication outcomes. Statins expenditures, especially...
Share
estimation of the consequences of reinforcing the 2016 and 2019 ESC/EAS guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care - a SwissDiab study
Source : https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwad178/7179456?login=false
AbstractBackground. In 2019, the ESC/EAS updated the 2016 guidelines for the management of dyslipidaemias recommending more stringent LDL-cholesterol (LDL-C) ta
Conclusions: For 68% of the patients, intensifying statin treatment and/or adding ezetimibe would be sufficient to reach the 2016 target, whereas 57% would require cost-intensive PCSK9i therapy to reach the 2019 target, with limited additional medium-term cardiovascular benefit.
Share
Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01857-w
Background Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary...
Conclusions: In patients with T2DM, evolocumab is an effective therapy to decrease noncalcified plaque volume necrotic volume, and increase calcified plaque volume. Furthermore, evolocumab could attenuate PCAT density, at least in part, via the reduction of lipoprotein(a).
Share
Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy - Journal of Nanobiotechnology
Source : https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-01904-4
PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration...
Conclusion: In the current study, we described the development of a (Lipo + M)@E nanoparticle to targeted deliver Evol into VSMCs of atherosclerotic plaque. The key findings of our study are that this compound (1) has good bionic properties, escapes immune cells phagocytose, and has long circulation time, (2) has good targeting...
Share
Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37183391/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
Share